Micardis®. Observational Study in Patients With Essential Hypertension

N/ACompletedNCT02200094

Boehringer Ingelheim4,532 enrolled

Overview

This study is designed to supplement, under conditions of usual clinical practice, the data on the efficacy and safety of Micardis® collected during the clinical studies.

Study Type

OBSERVATIONAL

Enrollment

4,532

Conditions

Hypertension

Interventions

Low dose of Telmisartan, once dailyDRUG

High dose of Telmisartan, once dailyDRUG

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patients of either sex over the age of 18 years suffering from essential hypertension requiring treatment according to the physician Exclusion Criteria: * Hypersensitivity to the active component or to any of the excipients * Pregnancy and lactation * Biliary obstructive disorders * Severe hepatic impairment * Severe renal impairment

Outcomes

Primary Outcomes

Changes in systolic and diastolic blood pressure

Time frame: Baseline, 4 weeks and 3 months after start of treatment

Percentage of patients with dose titration to 80 mg

Time frame: 4 weeks and 3 months after start of treatment

Number of patients with adverse events

Time frame: Up to 3 months after start of treatment

Global evaluation of treatment compliance by investigator, a 6-point rating scale

Time frame: 4 weeks and 3 months after start of treatment

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.